Sirtuins: Multifaceted drug targets

Current Molecular Medicine

Volumn 11, Issue 9, 2011, Pages 709-718

  Chakrabarty, S P ^a   Balaram, H ^b   Chandrasekaran, S ^c  

^a Aurigene Discovery Technologies Limited   (India)

^b JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

^c INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Activators; Inhibitors; Modulation of activity; Peptide conjugates; Sir2; Structure

Indexed keywords

HISTIDINE; LYSINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN P53; RESVERATROL; SIRTUIN 1; SIRTUIN 2; SIRTUIN 4; SIRTUIN 6; SURAMIN; SURFACTIN;

AGING; ARCHAEOGLOBUS FULGIDUS; ARTICLE; BIOCHEMISTRY; CHEMICAL GENETICS; CHEMICAL STRUCTURE; DEACETYLATION; DRUG BIOAVAILABILITY; DRUG TARGETING; GENETICS; HUMAN; HYPERICUM PERFORATUM; MINIMAL BRAIN DYSFUNCTION; MOLECULAR BIOLOGY; NEOPLASM; PHYSICAL CHEMISTRY; PLASMODIUM FALCIPARUM; PROTEIN TARGETING; THERMOTOGA MARITIMA; TRYPANOSOMA BRUCEI;

ANIMALS; BIOCATALYSIS; ENZYME ACTIVATION; ENZYME ACTIVATORS; ENZYME INHIBITORS; HUMANS; SIRTUINS;

EID: 81055155738     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411798062412     Document Type: Article

References (81)

1. Denu JM. Linking chromatin function with metabolic networks: Sir2 family of NAD(+)-dependent deacetylases. Trends Biochem Sci 2003; 28: 41-8.
2. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-59.
3. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53. by Sir2α promotes cell survival under stress. Cell 2001; 107: 137-48.
4. Cheng HL, Mostoslavsky R, Saito S, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)- deficient mice. Proc Natl Acad Sci USA 2003; 100: 10794-99.
5. Sakamoto J, Miura T, Shimamoto K, Horio Y. Predominant expression of Sir2 α, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett 2004; 556: 281-86.
6. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPARy. Nature 2004; 429: 771-76.
7. Sauve AA. Sirtuin chemical mechanisms. Biochem Biophys Acta 2010; 1804: 1591-603.
8. Sanders BD, Jackson B, Marmorstein R. Structural basis for sirtuin function: What we know and what we don't. Biochem Biophys Acta 2010; 1804: 1604-16.
9. Baur JA. Biochemical effects of SIRT1 activators. Biochem Biophys Acta 2010; 1804: 1626-34.
10. Cen Y. Sirtuins inhibitors: The approach to affinity and selectivity. Biochem Biophys Acta 2010; 1804: 1635-44.
11. Lawson M, Uciechowska U, Schemies J, Rumpf T, Jung M, Sippl W. Inhibitors to understand molecular mechanisms of NAD+-dependent deacetylases (sirtuins). Biochem Biophys Acta 2010; 1799: 726-39.
12. Lu S, Lin S. Regulation of yeast sirtuins by NAD+ metabolism and calorie restriction. Biochem Biophys Acta 2010; 1804: 1567-75.
13. Borra MT, Langer MR, Slama JT, Denu JM. Substrate specificity and kinetic mechanism of the Sir2 family of NAD+- dependent histone/protein deacetylases. Biochemistry 2004; 43: 9877-87.
14. Khan AN, Lewis PN. Use of substrate analogs and mutagenesis to study substrate binding and catalysis in the Sir2 family of NAD-dependent protein deacetylases. J Biol Chem 2006; 281: 11702-11.
15. Finnin MS, Donigian JR, Pavletich NP. Structure of the histone deacetylase SIRT2. Nat Struct Biol 2001; 8: 621-5.
16. Landry J, Slama JT, Sternglanz R. Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem Biophys Res Commun 2000; 278: 685-90.
17. Sauve AA, Schramm VL. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry 2003; 42: 9249-56.
18. Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM. Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem 2003; 278: 50985-98.
19. Sauve AA, Schramm VL. SIR2: the biochemical mechanism of NAD(+)-dependent protein deacetylation and ADP-ribosyl enzyme intermediates. Curr Med Chem 2004; 11: 807-26.
20. Kaplan N. In: The Enzymes; Boyer P, Ed. New York: Academic. 2nd Ed., 1960; Vol. 3: pp.105-64.
21. Tanner KG, Landry J, Sternglanz R, Denu JM. Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1- O-acetyl-ADP-ribose. Proc Natl Acad Sci USA 2000; 97: 14178-82.
22. Tanny JC, Moazed D. Coupling of histone deacetylation to NAD breakdown by the yeast silencing protein Sir2: Evidence for acetyl transfer from substrate to an NAD breakdown product. Proc Natl Acad Sci USA 2001; 98: 415-20.
23. Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of sirtuins. Annu Rev Biochem 2006; 75: 435-65.
24. Hawse WF, Hoff KG, Fatkins DG, et al. Structural insights into intermediate steps in the Sir2 deacetylation reaction. Structure 2008; 16: 1368-77.
25. Smith BC, Denu JM. Sir2 protein deacetylases: evidence for chemical intermediates and functions of a conserved histidine. Biochemistry 2006; 45: 272-82.
26. Ahuja N, Schwer B, Carobbio S, et al. Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J Biol Chem 2007; 282: 33583-92.
27. Haigis MC, Mostoslavsky R, Haigis KM, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic b cells. Cell 2006; 126: 941-54.
28. Liszt G, Ford E, Kurtev M, Guarente L. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J Biol Chem 2005; 280: 21313-20.
29. Kowieski TM, Lee S, Denu JM. Acetylation-dependent ADPribosylation by Trypanosoma brucei Sir2. J Biol Chem 2008; 283: 5317-26.
30. Merrick CJ, Duraisingh MT. Plasmodium falciparum Sir2: an unusual sirtuin with dual histone deacetylase and ADPribosyltransferase activity. Eukaryot Cell 2007; 6: 2081-91.
31. French JB, Cen Y, Sauve AA. Plasmodium falciparum Sir2 is an NAD+-dependent deacetylase and an acetyllysinedependent and acetyllysine-independent NAD+ glycohydrolase. Biochemistry 2008; 47: 10227-39.
32. Du J, Jiang H. Lin H. Investigating the ADP-ribosyltransferase activity of sirtuins with NAD analogues and 32P-NAD. Biochemistry 2009; 48: 2878-90.
33. Hawse WF, Wolberger C. Structure-based mechanism of ADP ribosylation by sirtuins. J Biol Chem 2009; 284: 33654-61.
34. Chen Y, Sprung R, Tang Y, et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics 2007; 6: 812-9.
35. Zhang K, Chen Y, Zhang Z, Zhao Y. Identification and verification of lysine propionylation and butyrylation in yeast core histones using PTMap software. J Proteome Res 2009; 8: 900-6.
36. Chen D, Bruno J, Easlon E, et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev 2008; 22: 1753-57.
37. Cheng Z, Tang Y, Chen Y, et al. Molecular characterization of propionyllysines in non-histone proteins. Mol Cell Proteomics 2009; 8: 45-52.
38. Smith BC, Denu JM. Acetyl-lysine analog peptides as mechanistic probes of protein deacetylases. J Biol Chem 2007; 282: 37256-65.
39. Finnin MS, Donigian JR, Pavletich NP. Structure of the histone deacetylase SIRT2. Nat Struct Biol 2001; 8: 621-5.
40. Avalos JL, Celic I, Muhammad S, Cosgrove MS, Boeke JD, Wolberger C. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol Cell 2002; 10: 523-35.
41. Zhao K, Chai X, Marmorstein R. Structure and substrate binding properties of cobB, a Sir2 homolog protein deacetylase from Escherichia coli. J Mol Biol 2004; 337: 731-41.
42. Min J, Landry J, Sternglanz R, Xu RM. Crystal structure of a SIR2 homolog-NAD complex. Cell 2001; 105: 269-79.
43. Avalos JL, Bever KM, Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell 2005; 17: 855-68.
44. Kim JE, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 2007; 28: 277-90.
45. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008; 451: 587-90.
46. Llorente B, Dujon B. Transcriptional regulation of the Saccharomyces cerevisiae DAL5 gene family and identification of the high affinity nicotinic acid permease TNA1 (YGR260w). FEBS Lett 2000; 475: 237-41.
47. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004; 279: 50754-63.
48. Gallo CM, Smith DL Jr, Smith JS. Nicotinamide clearance by Pnc1 directly regulates Sir2-mediated silencing and longevity. Mol Cell Biol 2004; 24: 1301-12.
49. Anderson RM, Bitterman KJ, Wood JG Medvedik O, Sinclair DA. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 2003; 423: 181-85.
50. North BJ, Verdin E Mitotic regulation of SIRT2 by cyclindependent kinase 1-dependent phosphorylation. J Biol Chem 2007; 282: 19546-55.
51. Pandithage R, Lilischkis R, Harting K, et al. The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol 2008; 180: 915-29.
52. Yang H, Yang T, Baur JA, et al. Nutrient sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007; 130: 1095-107.
53. Ohsawa S, Miura M. Caspase- apoptosis. FEBS Lett 2006; 580: 5875-79.
54. Schwer B, North BJ, Frye RA, Ott M, Verdin E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol 2002; 158: 647-57.
55. Ahuja N, Schwer B, Carobbio S, et al. Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J Biol Chem 2007; 282: 33583-92.
56. Nayagam VM, Wang X, Tan YC, et al. SIRT1 modulating compounds from high-throughput screening as antiinflammatory and insulin-sensitizing agents. J Biomol Screen 2006; 11: 959-67.
57. Bass TM, Weinkove D, Houthoofd K, Gems D, Partridge L. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech Ageing Dev 2007; 128: 546-52.
58. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
59. Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2006; 16: 296-300.
60. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005; 280: 17187-95.
61. Beher D, Wu J, Cumine S, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009; 74: 619-24.
62. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-6.
63. Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1. J Biol Chem 2010; 285: 8340-51.
64. Sauve AA, Moir RD, Schramm VL, Willis IM. Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol Cell 2005; 17: 595-601.
65. Sanders BD, Zhao K, Slama JT, Marmorstein R. Structural basis for nicotinamide inhibition and base exchange in Sir2 enzymes. Mol Cell 2007; 25: 463-72.
66. Takayashi S, Keiko I, Hidehiko N, Naoki M. 2- Anilinobenzamides as SIRT inhibitors. ChemMedChem 2006; 1: 1059-62.
67. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001; 276: 38837-43.
68. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 2001; 98: 15113-8.
69. Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006; 66: 4368-77.
70. Pagans S, Pedal A, North BJ, et al. SIRT1 regulates HIV transcription via tat deacetylation. PLoS Biol 2005; 3: e41.
71. Gey C, Kyrylenko S, Hennig L, et al. Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2. Angew Chem Int Ed Engl 2007; 46: 5219-22.
72. Schuetz A, Min J, Antoshenko T, et al. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure 2007; 15: 377-89.
73. Napper AD, Hixon J, McDonagh T, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005; 48: 8045-54.
74. Tendulkar SR, Saikumari YK, Patel V, et al. Isolation, purification and characterization of an antifungal molecule produced by Bacillus licheniformis BC98, and its effect on phytopathogen Magnaporthe grisea. J Appl Microbiol 2007; 103: 2331-9.
75. Chakrabarty SP, Saikumari YK, Bopanna MP, Balaram H. Biochemical characterization of Plasmodium falciparum Sir2, a NAD+-dependent deacetylase. Mol Biochem Parasitol 2008; 158: 139-51.
76. Trapp J, Jochum A, Meier R, et al. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem 2006; 49: 7307-16.
77. Smith BC, Denu JM. Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide. Biochemistry 2007; 46: 14478-86.
78. Asaba T, Suzuki T, Ueda R, Tsumoto H, Nakagawa H, Miyata N. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate. J Am Chem Soc 2009; 131: 6989-96.
79. Kolb HC, Finn MG, Sharpless KB. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angem Chem Int Ed Engl 2001; 40: 2004-21.
80. Chakrabarty SP, Ramapanicker R, Mishra R, Chandrasekaran, S, Balaram H. Development and characterization of lysine based tripeptide analogues as inhibitors of Sir2 activity. Bioorg Med Chem 2009; 17: 8060-72.
81. DeLano WL. Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 2002; 12: 14-20.